Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.
Storage & Handling:
The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. Test size products are transitioning from 20 µl to 5 µl per test. Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 µl staining volume or per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Read more at www.biolegend.com/testsize regarding the test size change.
COA:
Application Notes:
Additional reported applications (for the relevant formats) include: Western blot 1, immunopricipitation1, immunohistochemical staining2,3of paraffin embedded and frozen tissue sections, and ELISA4.
Application References:
1. Latza U, et al. 1994. Eur. J. Immunol. 24:677. (WB IP) 2. Durkop H, et al. 1995. Brit. J. Haematol. 91:927. (IHC) 3. Durkop H, et al. 1997. Brit. J. Haematol. 98:863. (IHC) 4. Willett B, et al. 2007. J. Virol. 81:9665. (ELISA)
Human peripheral blood lymphocytes were activated for 3 days with PHA, and then stained with CD3 FITC and OX-40 (clone Ber-ACT35) APC (top) or mouse IgG1, κ APC isotype control (bottom).
CD134, also known as OX40 and TNFRSF14, is a 50 kD type I transmembrane glycoprotein. It is a member of the TNF receptor family. OX40 is expressed on activated T lymphocytes including Th1, Th2, Th17, and Treg cells. The interaction of OX40 with OX40L results in B cell proliferation and antibody secretion, regulation of primary T cell expansion, and T cell survival. OX40 influences the size of the T cell memory pool and regulation of CD4+ T cell tolerance.
Other Names:
ACT35 antigen, tumor necrosis factor receptor superfamily member 4 (TNFRSF4)
Structure:
50 kD, TNF receptor family
Distribution:
Activated T cells
Function:
Receptor for OX40 ligand, co-stimulatory signal for T cell proliferation and survival
Ligand Receptor:
OX40L (CD252)
Antigen References:
1. Smith CA, et al. 1994. Cell 76:959. 2. Chen AL, et al. 1999. Immunity 11:689. 3. Croft M. 2010. Annu. Rev. Immunol. 28:57. 4. Ruby CE, et al. 2009. J. Immunol. 183:5079. 5. Klinger M, et al. 2009. J. Immunol. 182:4581.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.
FITC anti-human CD134 (OX40)
Human peripheral blood lymphocytes were activated for 3 days with PHA, and then stained with CD4 APC and OX-40 (clone Ber-ACT35) FITC (top) or mouse IgG1, κ FITC isotype control (bottom).
Purified anti-human CD134 (OX40)
Human peripheral blood lymphocytes were activated for 3 days with PHA, then stained with OX40 (clone Ber-ACT35) PE (filled histogram) or mouse IgG1, κ PE isotype control (open histogram).
PE anti-human CD134 (OX40)
3-day PHA-activated human peripheral blood lymphocytes were stained with OX-40 (clone Ber-ACT35) PE (filled histogram) or mouse IgG1, κ PE isotype control (open histogram).
APC anti-human CD134 (OX40)
Human peripheral blood lymphocytes were activated for 3 days with PHA, and then stained with CD3 FITC and OX-40 (clone Ber-ACT35) APC (top) or mouse IgG1, κ APC isotype control (bottom).
PerCP/Cy5.5 anti-human CD134 (OX40)
Human peripheral blood lymphocytes were activated for 3 days with PHA, and then stained with CD3 FITC and OX-40 (clone Ber-ACT35) PerCP/Cy5.5 (top) or mouse IgG1, κ PerCP/Cy5.5 isotype control (bottom).
PE/Cy7 anti-human CD134 (OX40)
PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD4 FITC and OX-40 (clone Ber-ACT35) PE/Cy7 (top) or mouse IgG1, κ PE/Cy7 isotype control (bottom).
Brilliant Violet 421™ anti-human CD134 (OX40)
PHA-stimulated (3-days) human peripheral blood lymphocytes were stained with CD3 FITC and OX-40 (clone Ber-ACT35) Brilliant Violet 421™ (top), or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).
